TCF7L2 and cancer: It has been well recognized that SE‐driven transcriptional dependencies can be effectively targeted by CDK7 inhibition therapy in various cancer types.[52] Therefore, we tested if CDK7 inhibition therapy could also work effectively on treating SOX9‐TCF7L2 double‐high GBC.